These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23104837)

  • 21. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
    Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
    Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
    Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
    Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences.
    Mariani L; Miceli R; Michilin S; Gion M
    Biomarkers; 2009 Mar; 14(2):130-6. PubMed ID: 19330591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
    Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
    Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
    Hui L; Rixv L; Xiuying Z
    Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CA 15-3 and CEA markers - prognostic factors in breast cancer].
    Anton E; Costăchescu G; Costăchescu G
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(1):161-4. PubMed ID: 12092146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
    Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. XAGE-1a and XAGE-1d are potential biomarkers of lung squamous cell carcinoma.
    Ha JS; Sung HY; Kim SY; Lim HM; Kim HK; Park SS
    Clin Chim Acta; 2012 Aug; 413(15-16):1226-31. PubMed ID: 22515959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
    Lumachi F; Brandes AA; Ermani M; Bruno G; Boccagni P
    Anticancer Res; 2000; 20(6C):4751-5. PubMed ID: 11205212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
    Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
    Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
    Salem AM; Zohny SF; Abd El-Wahab MM; Hamdy R
    Clin Biochem; 2007 Nov; 40(16-17):1201-8. PubMed ID: 17889845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.